Get the Stockscreener App
8.60
2.60%
-0.23
After Hours:
8.61
0.010
+0.12%
Enanta Pharmaceuticals Inc stock is traded at $8.60, with a volume of 221.93K.
It is down -2.60% in the last 24 hours and down -25.22% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$8.83
Open:
$8.92
24h Volume:
221.93K
Relative Volume:
1.37
Market Cap:
$182.27M
Revenue:
$73.62M
Net Income/Loss:
$-138.24M
P/E Ratio:
-1.3624
EPS:
-6.3125
Net Cash Flow:
$-99.19M
1W Performance:
-7.92%
1M Performance:
-25.22%
6M Performance:
-27.73%
1Y Performance:
-13.31%
1-Day Range:
$8.52
$9.11
1-Week Range:
$8.00
$9.69
52-Week Range:
$8.00
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
500 ARSENAL STREET, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.60 | 182.27M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com
ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartzy
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet - Simply Wall St
Enanta Pharmaceuticals (STU:9EP) Cash Flow from Operations : €-83.19 Mil (TTM As of Jun. 2024) - GuruFocus.com
Enanta stock touches 52-week low at $8.45 amid market challenges - Investing.com Canada
4 Analysts Assess Enanta Pharma: What You Need To Know - Benzinga
Leerink raises Enanta price target to $12 from $10, keeps rating - Investing.com UK
ENTA (Enanta Pharmaceuticals) Investments And Advances : $42.51 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Machinery, Furniture, Equipme - GuruFocus.com
ENTA (Enanta Pharmaceuticals) EBITDA per Share : $-5.02 (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Future 3-5Y EPS without NRI G - GuruFocus.com
Enanta Pharmaceuticals expands immunology portfolio - BioWorld Online
Enanta Pharmaceuticals shares target cut, rating held ahead of clinical trial results - Investing.com UK
ENTA (Enanta Pharmaceuticals) 3-Year Book Growth Rate : -23.20% (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) GF Value Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Debt-to-Asset : 0.13 (As of Jun. 2024) - GuruFocus.com
Enanta Pharmaceuticals Reports Q4 2024 Financials - TipRanks
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - BioSpace
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot - Marketscreener.com
Enanta Pharmaceuticals Inc Reports Q4 Loss of $1.36 Per Share, R - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Free Cash Flow per Share : $-4.75 (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) EBITDA : $-104.08 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) 14-Day RSI : 29.52 (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Debt-to-Revenue : 0.70 (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Issuance of Stock : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Change In Prepaid Assets : $1.81 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Net Issuance of Debt : $-7.17 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Forward Rate of Return (Yackt - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Other Long-Term Liabilities : $143.54 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) 5-Day RSI : 26.30 (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Other Current Liabilities : $32.30 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Long-Term Capital Lease Obligation : $48.14 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Purchase Of Investment : $-413.40 Mil (TTM As of Jun. 2024) - GuruFocus.com
Trend Tracker for (ENTA) - Stock Traders Daily
Enanta Pharma's Earnings Outlook - Benzinga
Enanta Pharmaceuticals (FRA:9EP) 3-Year Dividend Growth Rat - GuruFocus.com
Head to Head Analysis: CannTrust (OTCMKTS:CNTTF) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) - Defense World
ARMISTICE CAPITAL, LLC Adjusts Stake in Enanta Pharmaceuticals I - GuruFocus.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
(ENTA) Proactive Strategies - Stock Traders Daily
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):